Abstract

Alzheimer’s disease (AD) is one of the most common progressive neurodegenerative diseases, and the number of AD patients has increased year after year with the global aging trend. The onset of AD has a long preclinical stage. If doctors can make an initial diagnosis in the mild cognitive impairment (MCI) stage, it is possible to identify and screen those at a high-risk of developing full-blown AD, and thus the number of new AD patients can be reduced. However, there are problems with the medical datasets including AD data, such as insufficient number of samples and different data distributions. Transfer learning, which can effectively solve the problem of distribution discrepancy between training and test data and an insufficient number of target samples, has attracted increasing attention over recent years. In this paper, we propose a multi-source ensemble transfer learning (METL) approach by introducing ensemble learning and our tri-transfer model that uses Tri-Training, which ensures the transferability of source data by the tri-transfer model and high performance through ensemble learning. The experimental results on the benchmark and AD datasets demonstrate that our proposed approach has effective transferability, robustness, and feasibility, and is superior to existing algorithms. Based on METL, we propose an auxiliary diagnosis system for the initial diagnosis of AD, which helps doctors identify patients in the MCI stage as quickly as possible and with high accuracy so that measures can be taken to prevent or delay the occurrence of AD.

Highlights

  • Machine learning has shown great success in variety of application fields, including computer vision, object recognition, and natural language processing [1], [2]

  • Medical research shows that in the early stage of Alzheimer’s disease (AD), patients will present with mild cognitive impairment (MCI) [6], which lies between the normal state and the diseased state and begin to appear younger patients

  • If the MCI stage can be studied in depth, it is hoped that the high-risk population of AD will be discovered and screened, providing an optimal treatment time window for preventing or delaying the occurrence of AD

Read more

Summary

Introduction

Machine learning has shown great success in variety of application fields, including computer vision, object recognition, and natural language processing [1], [2]. Medical research shows that in the early stage of AD, patients will present with mild cognitive impairment (MCI) [6], which lies between the normal state and the diseased state and begin to appear younger patients. Many studies are based on the hope that potential AD patients can be detected during the MCI stage, and effective measures can be taken to prevent the disease from worsening. If early prevention and treatment are available, the number of new patients will be reduced. If the MCI stage can be studied in depth, it is hoped that the high-risk population of AD will be discovered and screened, providing an optimal treatment time window for preventing or delaying the occurrence of AD. The Alzheimer’s Disease Neuroimaging Initiative (ADNI) [7] provides researchers committed to determining the progression of AD with research data.

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call